title: A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.
abstract: Several agents in a new class of antiemetic compounds, 5-hydroxytryptamine (5-HT3) antagonists, have shown promise as effective antiemetics with fewer side effects than metoclopramide. One of these agents, batanopride, produced no severe toxicity at doses that prevented emesis due to chemotherapy in early Phase I trials. We conducted a randomized, double-blinded, 7 arm clinical trial to: (1) identify the presence of a dose-response for complete protection from emesis, and (2) compare batanopride with a standard antiemetic, methylprednisolone if a dose-response was found not to exist. Prior to chemotherapy, six patient groups each received a single intravenous dose of batanopride ranging from 0.2 to 6.0 mg/kg whereas a seventh group received methylprednisolone 250 mg intravenously. Chemotherapy-naïve cancer patients scheduled to receive moderately emetogenic chemotherapy were eligible. Primary treatment outcomes that were recorded and analyzed included the number of episodes of emesis, the time to the first episode of emesis as well as the frequency and severity of nausea. Two hundred and eight patients accrued between April 1989 and February 1990 were evaluable for response. A significant dose-response effect for complete protection from emesis was not seen over the first 24 hours after chemotherapy (p = 0.102). However, a linear dose-response effect for time to first emesis was evident in a multivariate analysis (p = 0.029). While the highest batanopride dose group was associated with a higher complete protection rate (CPR) than the control group, this group also exhibited a higher incidence of diarrhea (p = 0.013), hypotension, and electrocardiographic abnormalities.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, McMaster University, Hamilton Regional Cancer Centre, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Rusthoven
authors.forename: J
authors.initials: J
authors.lastname: Pater
authors.forename: L
authors.initials: L
authors.lastname: Kaizer
authors.forename: K
authors.initials: K
authors.lastname: Wilson
authors.forename: D
authors.initials: D
authors.lastname: Osoba
authors.forename: J
authors.initials: J
authors.lastname: Latreille
authors.forename: B
authors.initials: B
authors.lastname: Findlay
authors.forename: W S
authors.initials: WS
authors.lastname: Lofters
authors.forename: D
authors.initials: D
authors.lastname: Warr
authors.forename: F
authors.initials: F
authors.lastname: Laberge
mesh_terms: D000293:Adolescent; D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D015993:Life Tables; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008787:Metoclopramide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015999:Multivariate Analysis; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D012702:Serotonin Antagonists; C060190:batanopride; D008787:Metoclopramide; D008775:Methylprednisolone